28.8 C
New York
Sunday, June 14, 2026

Tag: file

newssourceFORcompanyinformationcontent1marketreleases

FLYWIRE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff...

NEW YORK CITY and NEW ORLEANS, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 23, 2025 to file lead plaintiff applications in a securities class action lawsuit against Flywire Corporation (“Flywire” or the “Company”) (NasdaqGS: FLYW), if they purchased the Company’s securities between February 28, 2024 and February 25, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York.

HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000...

NEW YORK and NEW ORLEANS, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased the Company’s securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.

Cavvy Releases Q2 2025 Financial and Operating Results

Third Party Processing Growth and Strong Hedging Gain Bolsters Cash Flow, Drives Debt Reduction 
Third Party Processing Growth and Strong Hedging Gain Bolsters Cash Flow, Drives Debt Reduction

Argenta Silver Announces Closing of Additional Investment of C$2.5 Million

TSX-V:AGAG VANCOUVER, BC, Aug. 12, 2025 /CNW/ - Argenta Silver Corp. (TSXV: AGAG) (FSE: T1K) ("Argenta" or the "Company") is pleased to announce the closing of...

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with Janus Henderson Investors, a global asset management firm, for the purchase and sale of 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period. 

Terrestrial Energy Selected for DOE Office of Nuclear Energy Advanced Reactor Pilot Program for Accelerated Development

Advanced Reactor Pilot Program launched by DOE to expedite authorization and commercialization of advanced nuclear reactor designs

SendCutSend Doubles Down on Business Tools as More Teams Tap Into Enterprise Features

Company Joins Inc. 5000 List for Third Straight Year RENO, Nev., Aug. 12, 2025 /PRNewswire/ -- As more companies turn to fast, flexible American manufacturing, SendCutSend...

TEAMSTERS FIGHT FOR AREA STANDARDS AT GM CARHAUL CONTRACTORS IN BOWLING GREEN

Union Carhaulers Demand Fair Wages and Benefits from Non-Union Operators   BOWLING GREEN, Ky., Aug. 12, 2025 /PRNewswire/ -- Teamsters carhaul drivers will hold an area...

Argenta Silver Announces Closing of Bought Deal Private Placement for Gross Proceeds of C$15 Million

/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/              ...

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

AmpliTech Group To Release Q2 – 2025 Earnings On August 14th After Market Also Announces Investor’s Conference Call

AmpliTech Group To Release Q2 – 2025 Earnings On August 14th After Market Also Announces Investor’s Conference Call

VEON’s Kyivstar Delivers First Messages via Starlink in Direct to Cell Satellite Connectivity Test in Ukraine

Dubai and Kyiv, August 12, 2025 – VEON Ltd. (Nasdaq: VEON), a global digital operator, today announces that Kyivstar, its digital operator in Ukraine, has successfully conducted a test of satellite and terrestrial network integration using Starlink Direct to Cell technology. This is the first field test of of Starlink Direct to Cell in eastern Europe. 

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFile

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers